The present invention relates to a Lactobacillus sakei CVL-001 strain and a method for isolating same, wherein the strain is lactic acid bacteria which can be isolated from kimchi, and thus can be effectively used as a probiotic or food additive. Furthermore, the present invention relates to a composition for improving, preventing, or treating bone diseases or metabolic diseases, including Lactobacillus sakei CVL-001 strain (Lactobacillus sakei) or a culture medium thereof, wherein the Lactobacillus sakei strain isolated from kimchi and the culture medium thereof exhibit the effects of suppressing osteoclast differentiation, improving osteoporosis, suppressing adipocyte differentiation, and suppressing weight gain, and thus can be effectively used for the improvement, prevention, or treatment of osteoporosis or obesity related diseases.

A Lactobacillus reuteri ATG-F4 strain (Accession number KCTC13717BP) is proposed. The strain has the function of enhancing dopamine secretion, and thus can be used as a pharmaceutical composition or a functional health food for the prevention or amelioration of mental illnesses, such as memory disorder, depressive disorder, generalized anxiety disorder, bipolar disorder, and the like, as well as Parkinson's disease, or can be used as a very effective composition for the improvement of memory or cognitive function. Moreover, the strain exhibits anti-inflammatory efficacy of upregulating the expression of IL-10 (interleukin-10) and inhibiting the generation of nitric oxide (NO) and is not resistant to antibiotics, and can thus be readily applied to a variety of foods having health improvement effects.

Compositions are provided for providing support to companion animals affected by Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). In some embodiments, the composition comprises at least one isolated strain of wolf probiotic bacteria and at least one isolated strain of canine probiotic bacteria. In some embodiments, the composition further comprises at least one prebiotic. Also provided are related methods for preparing a composition and for treating IBS and/or IBD in a subject.

The present invention addresses the problem of providing a novel production method of a plant protein food. This method comprises treating a starting plant protein material with both of a lipase and a protein deamidase (for example, protein glutaminase) to thereby improve the flavor of a plant protein food.

The present invention in particular relates to the identification of novel Lactobacillus mudanjiangensis strains which are characterized in having a whole genome GC content of less than 43%. Moreover, these strains are characterized by the expression of a novel cellulase enzyme, which has numerous applications in the fields of for example agriculture, bioconversion, detergents, fermentation, food, paper industry, or textile industry.

The invention is directed to recombinant bacteria, a recombinant plasmid, a pharmaceutical composition and a kit as well as the use of a reconstitution medium comprising chloride ions to reconstitute the recombinant bacteria.

Microbiome compositions and uses thereof. The microbiome compositions include a set of microbes. The sets of microbes contain members of Lactobacillaceae, Eubacteriaceae, Lachnospiraceae, and Coriobacteriaceae. The number of individual physical microbes in the set constitutes a certain percentage of the total number of individual physical microbes in the microbiome composition. The microbiome compositions can be used for producing medium-chain fatty acids from organic substrates through anaerobic fermentation in a medium. The medium can include lignocellulosic stillage.

The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a Lactobacillus sp which colonizes the gastrointestinal tract. The anti-infective activity can be a bacteriocidal or bacteriostatic peptide, an antibody or fragment thereof which specifically recognizes a pathogen, or a phage, or a lytic peptide from a phage which specifically targets a certain pathogen.

The invention herein discloses histamine-producing bacterial strains for use in the prophylaxis, inhibition, treatment or reducing a risk of relapse of cancer, including colorectal cancer. The present invention also discloses the use of histamine-producing bacterial strains for manufacturing a medicament for treatment of cancer, including male colorectal cancer.

Provided herein are fermented beverages comprising symbiotic microbial communities, and methods of production thereof.